Premium
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
Author(s) -
QuintásCardama Alfonso,
Cortes Jorge E.,
O'Brien Susan,
Ravandi Farhad,
Borthakur Gautam,
Liu David,
Bleickardt Eric,
Chen TaiTsang,
Kantarjian Hagop M.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24325
Subject(s) - dasatinib , imatinib , medicine , myeloid leukemia , tyrosine kinase inhibitor , oncology , gastroenterology , cancer
BACKGROUND: Although many patients with chronic myeloid leukemia (CML) respond well to imatinib therapy, a significant proportion loses their initial response. Loss of response on imatinib is often because of BCR‐ABL mutations. Dasatinib is a 325‐fold more potent inhibitor of Bcr‐Abl than imatinib and has been associated with high rates of durable responses in patients with CML in chronic phase (CP) after imatinib failure. METHODS: To determine the optimal time for initiating dasatinib after loss of response on imatinib, data from dasatinib trials in CML‐CP were analyzed. Patients were grouped according to whether they received early intervention with dasatinib (ie, after cytogenetic recurrence on imatinib), rather than after both cytogenetic and hematologic recurrence. RESULTS: Overall, 72% of patients who received dasatinib after loss of a major cytogenetic response (MCyR) on imatinib achieved a complete cytogenetic response (CCyR) compared with 42% of patients who were treated after loss of both MCyR and complete hematologic response (CHR). Event‐free survival (EFS) also was higher after earlier dasatinib treatment (24‐month EFS rates: 89% after loss of MCyR on imatinib vs 29% after loss of both MCyR and CHR). Among patients who were treated after loss of CHR on imatinib with no prior MCyR, 26% achieved a CCyR with dasatinib, and the 24‐month EFS rate was 64%. In all 3 groups, CCyR rates were similar in patients with or without pre‐existing BCR‐ABL mutations. CONCLUSIONS: The results of the current study suggested that optimal outcomes are achieved when dasatinib is administered early after imatinib resistance. Cancer 2009. © 2009 American Cancer Society.